儿童克罗恩病进展与抗肿瘤坏死因子时机及体重指数Z评分正常化相关
该多中心5年纵向研究纳入1075例新诊断儿童克罗恩病患者,分析抗肿瘤坏死因子(aTNF)使用时机和体重指数z评分(BMIz)正常化与复杂疾病行为及手术风险的关系。结果显示诊断3个月内使用aTNF与B1向B2进展风险降低相关(HR 0.33),低BMIz患儿诊断6个月内BMIz正常化与手术风险降低相关(HR 0.47)。
要点
- 诊断3个月内使用aTNF与B1向B2进展风险降低相关(HR 0.33;95%CI 0.15-0.71)。
- 低BMIz患儿诊断6个月内BMIz正常化与手术风险降低相关(HR 0.47;95%CI 0.26-0.85)。
- 诊断时B2(HR 4.20)和B2+B3(HR 8.24)增加手术风险;未BMIz正常化者富集细胞因子产生和炎症基因。
核心结论
- 诊断后3个月内使用aTNF可能减少B1向B2进展。
- 诊断后6个月内未实现BMIz正常化与手术风险增加及促炎转录组谱相关。
研究设计与样本
- 多中心、5年纵向数据,纳入1075例新诊断儿童克罗恩病患者。
- 采用描述性统计、单因素和逐步多因素Cox比例风险回归(CPHR)及log-rank分析,评估手术和复杂疾病行为风险。
- 回肠批量RNA测序的差异基因表达与结局进行关联分析。
主要发现
- 狭窄并发症增幅最大:5年内从2.98%增至10.60%。
- 多因素CPHR显示,诊断后3个月内aTNF暴露(HR 0.33;95%CI 0.15-0.71)和基线L2病变(HR 0.29;95%CI 0.09-0.92)与B1向B2进展风险降低相关。
- 诊断时低BMIz患儿(n=294)中,多因素CPHR显示诊断后6个月内BMIz正常化(HR 0.47;95%CI 0.26-0.85)和5-氨基水杨酸暴露(HR 0.32;95%CI 0.13-0.81)与手术风险降低相关。
- 诊断时B2(HR 4.20;95%CI 1.66-10.65)和B2+B3(HR 8.24;95%CI 1.08-62.83)增加手术风险。
- 未实现BMIz正常化的患者富集细胞因子产生和炎症相关基因。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The evolution of complicated pediatric Crohn's disease (CD) in the era of anti-tumor necrosis factor (aTNF) therapy continues to be described. Because CD progresses from inflammatory to stricturing (B2) and penetrating (B3) disease behaviors in a subset of patients, we aimed to understand the risk of developing complicated disease behavior or undergoing surgery in relation to aTNF timing and body mass index z-score (BMIz) normalization. METHODS: Multicenter, 5-year longitudinal data from 1075 newly diagnosed CD patients were analyzed. Descriptive statistics, univariate and stepwise multivariate Cox proportional hazard regression (CPHR), and log-rank analyses were performed for risk of surgery and complicated disease behaviors. Differential gene expression from ileal bulk RNA sequencing was correlated with outcomes. RESULTS: Stricturing complications had the largest increase: from 2.98% to 10.60% over 5 years. Multivariate CPHR showed aTNF exposure within 3 months from diagnosis (hazard ratio [HR], 0.33; 95% CI, 0.15-0.71) and baseline L2 disease (HR, 0.29; 95% CI, 0.09-0.92) to be associated with reduced B1 to B2 progression. For children with a low BMIz at diagnosis (n = 294), multivariate CPHR showed BMIz normalization within 6 months of diagnosis (HR, 0.47; 95% CI, 0.26-0.85) and 5-aminosalicyclic acid exposure (HR, 0.32; 95% CI, 0.13-0.81) were associated with a decreased risk for surgery while B2 (HR, 4.20; 95% CI, 1.66-10.65) and B2+B3 (HR, 8.24; 95% CI, 1.08-62.83) at diagnosis increased surgery risk. Patients without BMIz normalization were enriched for genes in cytokine production and inflammation. CONCLUSIONS: aTNF exposure up to 3 months from diagnosis may reduce B2 progression. In addition, lack of BMIz normalization within 6 months of diagnosis is associated with increased surgery risk and a proinflammatory transcriptomic profile.
引用
- Geem D, Hercules D, Pelia RS, et al. Progression of Pediatric Crohn's Disease Is Associated With Anti-Tumor Necrosis Factor Timing and Body Mass Index Z-Score Normalization. Clin Gastroenterol Hepatol. 2023. PMID: 37802268. doi:10.1016/j.cgh.2023.08.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。